Blood Pressure Drug for COVID-Induced Lung Injury?
Despite promising results in preclinical models, angiotensin-receptor blockade with losartan did not reduce lung injury in hospitalized COVID-19 patients in this randomized clinical trial.
Medscape Medical News
source https://www.medscape.com/viewarticle/972136?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/972136?src=rss
Comments
Post a Comment